News | April 14, 2026
Roche wins CE mark for blood-based MS brain damage test
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
The new test offers a minimally invasive blood-based approach to tracking neurological damage, measuring neurofilament light chain
Final approval for progesterone vaginal inserts expands Glenmark’s women’s healthcare portfolio in the US, targeting a market of over $59 million
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
Opioid dependence remains a major driver of death and disease worldwide
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
The Institute of Human Biology (IHB) enables scientists to pioneer human model systems, accelerating the development of new medicines to improve the lives of patients
This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing
These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions
Subscribe To Our Newsletter & Stay Updated
